GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » Cyclically Adjusted Revenue per Share

Predictive Oncology (Predictive Oncology) Cyclically Adjusted Revenue per Share : $220.00 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Predictive Oncology's adjusted revenue per share for the three months ended in Dec. 2023 was $0.082. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $220.00 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Predictive Oncology's average Cyclically Adjusted Revenue Growth Rate was -38.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -23.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -16.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Predictive Oncology was -8.30% per year. The lowest was -23.40% per year. And the median was -13.30% per year.

As of today (2024-04-30), Predictive Oncology's current stock price is $1.41. Predictive Oncology's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $220.00. Predictive Oncology's Cyclically Adjusted PS Ratio of today is 0.01.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Predictive Oncology was 0.39. The lowest was 0.01. And the median was 0.04.


Predictive Oncology Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Predictive Oncology's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Cyclically Adjusted Revenue per Share Chart

Predictive Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 544.62 489.23 470.01 355.22 220.00

Predictive Oncology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 355.22 301.98 243.60 231.57 220.00

Competitive Comparison of Predictive Oncology's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Cyclically Adjusted PS Ratio falls into.



Predictive Oncology Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Predictive Oncology's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.082/129.4194*129.4194
=0.082

Current CPI (Dec. 2023) = 129.4194.

Predictive Oncology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 70.000 99.695 90.871
201406 318.000 100.560 409.264
201409 397.000 100.428 511.606
201412 166.000 99.070 216.854
201503 151.000 99.621 196.167
201506 234.000 100.684 300.784
201509 86.000 100.392 110.867
201512 183.000 99.792 237.330
201603 24.250 100.470 31.237
201606 6.538 101.688 8.321
201609 7.941 101.861 10.089
201612 6.087 101.863 7.734
201703 5.469 102.862 6.881
201706 3.452 103.349 4.323
201709 4.935 104.136 6.133
201712 6.667 104.011 8.296
201803 7.228 105.290 8.884
201806 6.085 106.317 7.407
201809 5.000 106.507 6.076
201812 4.216 105.998 5.148
201903 3.228 107.251 3.895
201906 0.953 108.070 1.141
201909 3.331 108.329 3.979
201912 1.856 108.420 2.215
202003 1.214 108.902 1.443
202006 0.372 108.767 0.443
202009 0.640 109.815 0.754
202012 0.297 109.897 0.350
202103 0.153 111.754 0.177
202106 0.136 114.631 0.154
202109 0.096 115.734 0.107
202112 0.145 117.630 0.160
202203 0.096 121.301 0.102
202206 0.104 125.017 0.108
202209 0.116 125.227 0.120
202212 0.092 125.222 0.095
202303 0.060 127.348 0.061
202306 0.123 128.729 0.124
202309 0.177 129.860 0.176
202312 0.082 129.419 0.082

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Predictive Oncology  (NAS:POAI) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Predictive Oncology's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.41/220
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Predictive Oncology was 0.39. The lowest was 0.01. And the median was 0.04.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Predictive Oncology Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology (Predictive Oncology) Business Description

Traded in Other Exchanges
N/A
Address
2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Executives
Robert L Myers officer: CHIEF FINANCIAL OFFICER 4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr director 633 1ST STREET WEST, SONOMA CA 95476
Veena Rao director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr director 1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch director P O BOX 1572, PEPPERELL MA 01463
Pamela Bush officer: Chief Business Officer 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley director 1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith director 151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle director 1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz 10 percent owner 20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel director 900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121